Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth

Table 2 Relationship between tuftelin 1 and clinicopathological characteristics in hepatocellular carcinoma patients

Group	n	TUFT1 expression		Pearson χ2	P value
		Low	High
AFP (ng/mL)				2.901	0.089
< 20	28	18	10
≥ 20	104	48	56
HBsAg				3.300	0.069
Neg.	12	9	3
Pos.	120	57	63
HBeAg				4.080	0.043
Neg.	87	49	38
Pos.	45	17	28
Tumor size (cm)				9.388	0.002
< 3	26	20	6
≥ 3	106	46	60
Differentiation degree				3.013	0.083
Well-Med.	19	13	6
Poor	113	53	60
Vascular invasion				14.885	< 0.001
With	58	18	40
Without	74	48	26
Ascites				5.940	0.015
With	32	10	22
Without	100	56	44
TNM staging				13.516	< 0.001
I-II	59	40	19
III-IV	73	26	47

AFP: Alpha-fetoprotein; HBeAg: Hepatitis B virus e antigen; HBsAg: Hepatitis B virus surface antigen; HCC: Hepatocellular carcinoma; Neg: Negative expression; Pos: Positive expression; TUFT1: Tuftelin 1.